In the EU5, access to disease-modifying therapies (DMTs) for the treatment of multiple sclerosis is impacted by multiple factors including specific indication labeling, monitoring requirements, health technology assessment decisions, patient access agreements, and regional variations in reimbursement. New therapies, including late-phase pipeline products (Novartis’s siponimod, Celgene’s ozanimod, Actelion’s ponesimod, and Novartis’s ofatumumab) and recent entrants whose HTAs are still under way (Roche’s Ocrevus and Merck’s Mavenclad) will be required to demonstrate cost-effectiveness and therapeutic benefit over existing brands to optimize pricing and reimbursement terms. Additionally, competition from emerging generics (glatiramer acetate, fingolimod) will introduce a new dynamic into pricing and reimbursement decisions in what has been a brand-only market.
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
Markets covered: France, Germany, Italy, Spain, United Kingdom.
Key companies: Roche, Merck, Novartis, Receptos, Celgene.
Key drugs: established disease-modifying therapies, and recently-launched/emerging therapies such as Ocrevus, Mavenclad, siponimod, and ozanimod.